Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
In SYNCHRONIZE-1, survodutide achieved significant weight loss in people with obesity or overweight without diabetes, with reported mean weight loss up to 16.6% after 76 weeks
Educate patients about exercise A 2024 study by researchers from the University of Copenhagen*3 shows that exercise in conjunction with tapering helps prevent rebound weight gain
It is given as a weekly injection straight into the stomach, thigh or upper arm
The concept of resetting the hunger switch is both physiologically complex and scientifically debated
HealOS Denial Management agents assist appeals
With this acquisition, Roche aimed to strengthen its metabolic disease franchise by gaining access to Carmots advanced portfolio, particularly a phase-2-ready dual GLP-1/GIP receptor agonist, thereby enhancing its competitive position in both obesity and diabetes markets
US$ 26.89
US$ 22.75
US$ 20.17
US$ 26.75
US$ 26.84
US$ 26.80
US$ 22.16
